Good analysis Cynical. The Alpha article did not think about any of those landmarks when he wrote it. He is only talking about money which we should enough to get us through the whole of next year. The cash burn should decrease for the ALS trial because they have orphan drug designation. One of the benefits is that the trial cost is offset.
The depression trial huge in my opinion because of the market for it. It could be prescribed for Alzheimers, depression, dementia, and for many brain related problems. This one drug if successful would push this company to the forefront of drug companies. Double I believe is conservative.
Thanks for your incite Cyanical
Good luck
Market Data 
Markets 
AI
